Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2017-12-07

Clinical Trial Update: A Study With ASP2151 in Subjects With Recurrent Episodes of Genital Herpes [Phase 2]

View source ↗

Summary

A Phase 2 study of ASP2151 in subjects with recurrent genital herpes has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • ASP2151

Snippet

Sponsor: Astellas Pharma Inc | Conditions: Herpes Genitalis | Phase 2 | Status: COMPLETED